WHO ICTRP trial
In- Vivo Bioequivalence study of Oxycodone tablet 40 mg Alborz Pharmed (LENITON®…
IRCT20200105046010N69 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20200105046010N69 |
|---|---|
| Public title | In- Vivo Bioequivalence study of Oxycodone tablet 40 mg Alborz Pharmed (LENITON® ER 40mg Tab.) with brand drugs (OLBETE® ER 40 mg Tab.,Purdue Pharma LP, UK) in Iranian healthy volunteers |
| Scientific title | In- Vivo Bioequivalence study of Oxycodone ER tablets 40 mg Alborz Pharmed with brand drugs (OLBETE® ER. 40 mg, Purdue Pharma LP, UK) in Iranian healthy volunteers. |
| Primary sponsor | Alborz Pharmed Pharmaceutical Co. |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | Bio equivalence test. |
| Interventions | Intervention 1: Intervention group: One test tablet (Oxycodone ER tablets 40 mg Alborz Pharmed) will be received. Blood samples will be taken for 24 hours at the mentioned times after drug administration and the concentration of the drug in… |
| Registration date | Oct 16, 2022 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: